Knowing what is important in life became clear to Michael and Kim Jones after Michael was diagnosed with terminal neck cancer. “It changed us dramatically,” Kim said of the diagnosis and the ensuing five-year journey that followed.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7100755-northwestern-mutual-client-stories-life-insurance/
Click: http://www.melogia.com New Folk Indie Top 40 song "What If I Never See You Again" by Sarantos.
Questions that will run through one's mind as they deal with the death of a parent are too numerous to list. Sarantos knows this firsthand since his father passed away after a long, hard fought battle with lung cancer. Sarantos captures the essence of this frustration and exasperation one sleepless night and this folk song was born. The song, melody, rhythm and length fit the mood and feel of this tortured night.
33% of any music-related sales profits from this song are going straight to The National Center For Fathering.
Additional Links:
https://www.facebook.com/Sarantosmelogia
http://www.twitter.com/sarantosmelogia
http://www.youtube.com/user/SarantosMelogia
http://bit.ly/SarantosAppleStore
Currently melanoma is the deadliest form of skin cancer and one of the most common cancers in women under 40 years old in the United States. The first line of defense in helping to reduce the risk of developing melanoma is by wearing broad spectrum UVA and UVB SPF protection. L’Oréal Paris, a leading global beauty brand, and Melanoma Research Alliance (MRA), the leading private funder of melanoma research, announced today the launch of It’s THAT Worth It To Me. This social media campaign encourages women to donate 15 social media seconds by sharing why SPF protection or using sunless tanner is worth it to protect their skin, their beauty and their life. For every social share, L’Oréal Paris will donate $1 to MRA to fund the L’Oréal Paris - MRA Team Science Award Research Grant, up to $250,000 in 2015.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7459051-l-oreal-paris-mra-it-s-that-worth-it/
Featuring a noted cancer researcher, animal behaviorists and a 14-year-old entrepreneur who developed a new product to ease pets’ separation anxiety, Purina’s second Better With Pets Summit emphasized how technology and scientific advances are leading to a brighter future with our pets. The daylong event, Tuesday, in New York City featured 15 expert presentations on scientific, nutritional and behavioral innovations to help better understand why our lives are better with pets.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7325551-purina-better-with-pets-summit-2014/
L’Oréal announced the winners of its International Awards for Social Responsibility in Dermatology, “Caring to Inspire Skin Confidence” at the 23rd World Congress of Dermatology taking place in Vancouver, Canada.
For Latin America
Dr. Gioconda Gaudiano from Republic of Panama
Moon Children - Providing mobile surgery clinics to Indigenous people
This initiative provides free consultations, medical treatment and sun education via mobile surgery clinics to the 40,000 indigenous people from the Archipelago of San Blas, a region with the highest incidence of albinism in the world. Albinos can face severe skin problems, such as skin cancer, caused by UV light and sun exposure due to the lack of melanin in their skin. The mobile surgery clinics are able to travel to the Archipelago of San Blas, a community that often shuns medical treatment and avoids protective measures against skin cancer.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7554651-loreal-announces-2015-awardees/
Supergoop!® announces its partnership with entrepreneur and international tennis sensation Maria Sharapova, welcoming her to the Supergoop! team as a co-owner with Founder and CEO Holly Thaggard. Supergoop! is the first and only multi-functional skincare line in prestige distribution with a foundation in UV protection and 100% dedication to sun safety. This partnership will be a vehicle for Supergoop! to spotlight the brand’s mission to elevate skin cancer awareness alongside the many skincare and beauty benefits attributed to applying UV protection every single day.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/7190451-supergoop-partnership-tennis-maria-sharapova-sun-protection-skincare
Today, the American Lung Association's LUNG FORCE initiative is joining forces with Academy Award®-nominated actress, Laura Dern, country music star Kellie Pickler, and Emmy- and Golden Globe-winning actress, Valerie Harper, during National Women’s Lung Health Week (May 10th -16th) to share their voices in an effort to defeat lung cancer in women.
Every eight minutes, a woman in the United States dies of lung cancer. It is the #1 cancer killer of women, killing almost twice as many women as any other cancer. Yet, awareness is extremely low. Only 1 percent of women cite lung cancer as a women’s cancer that is top-of-mind for them, according to the American Lung Association's Women's Lung Health Barometer. Now in its second year, LUNG FORCE, in partnership with national presenting sponsor, CVS Health, is empowering women and men everywhere to share their voices and make lung cancer a public health priority.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7521751-ala-lung-force-cancer-women/
Today, the Pharmaceutical Research and Manufacturers of America (PhRMA) released a new report, “A Decade of Innovation in Rare Diseases,” to document the significant progress made in the last 10 years in understanding a broad range of rare diseases and translating this knowledge into groundbreaking therapies for a variety of patient populations.
The report illustrates that more than 230 new medicines to treat rare or “orphan” diseases were approved by the U.S. Food and Drug Administration (FDA) in the last decade, and there are currently more than 450 orphan drugs in development.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7350554-phrma-report-innovation-rare-diseases/
Janssen-Cilag International NV (Janssen) announced today that the European Commission has approved IMBRUVICA™ (ibrutinib) capsules, a first-in-class, once-daily, oral Bruton’s tyrosine kinase (BTK) inhibitor. This new approach to treating blood cancers works by blocking BTK, a protein that helps certain cancer cells live and grow.1 IMBRUVICA is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL), or adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy, or in first line in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/72762540-janssen-ec-approval-imbruvica-mcl-cll/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Phenogen Sciences, Inc. today announced the availability of BREVAGenplus, an easy-to-use predictive risk test for the millions of women at risk of developing sporadic, or non-hereditary, breast cancer. The test is an enhancement of the company’s first generation product, BREVAGen®. BREVAGenplus assesses both clinical risk factors and genetic markers known to be associated with sporadic, or non-hereditary, breast cancer to determine a woman’s five-year and lifetime risk of developing the disease. The test is designed to facilitate better informed decisions about breast cancer screening and preventive treatment plans for Caucasian, Hispanic and African-American women, age 35 years or above, who have not had breast cancer, lobular carcinoma in situ (LCIS) or ductal carcinoma in situ (DCIS), and have one or more risk factors for developing breast cancer.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7337351-phenogen-sciences-introduces-brevagenplus-breast-cancer-risk-assessment-test/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
